Biology:Follistatin
Follistatin, also known as activin-bindings protein, is a protein that in humans is encoded by the FST gene.[1][2] Follistatin is an autocrine glycoprotein that is expressed in nearly all tissues of higher animals.[2]
Its primary function is the binding and bioneutralization of members of the TGF-β superfamily, with a particular focus on activin, a paracrine hormone.
An earlier name for the same protein was FSH-suppressing protein (FSP). At the time of its initial isolation from follicular fluid, it was found to inhibit the anterior pituitary's secretion of follicle-stimulating hormone (FSH).
Biochemistry
Follistatin is part of the inhibin-activin-follistatin axis.
Three isoforms, FS-288, FS-300, and FS-315 have been reported. Two, FS-288 and FS-315, are created by alternative splicing of the primary mRNA transcript. FS-300 (porcine follistatin) is thought to be the product of posttranslational modification via truncation of the C-terminal domain from the primary amino-acid chain.
Although FS is ubiquitous, its highest concentration is in the female ovary, followed by the skin.
Follistatin is produced by folliculostellate (FS) cells of the anterior pituitary. FS cells make numerous contacts with the classical endocrine cells of the anterior pituitary including gonadotrophs.
Function
In tissues, activin plays a significant role in cellular proliferation, while follistatin acts as safeguard against uncontrolled cellular proliferation and an instrument of cellular differentiation. These roles are vital for rebuilding and repairing tissue, and may account for the high prevalence of follistatin in the skin.
In the blood, activin and follistatin are involved in the inflammatory response following tissue injury or pathogenic incursion. The source of follistatin in circulating blood plasma has yet to be determined; however, endothelial cells (lining blood vessels), or macrophages and monocytes (circulating within the blood) have been proposed as likely origins, given its autocrine nature.
Follistatin acts as an inhibitor for bone morphogenic proteins (BMPs) involved in embryo development. Since BMPs facilitate the ectoderm becoming the epidermal ectoderm, their inhibition allows the ectoderm to become the neuroectoderm - eventually forming the neural plate. Other inhibitors involved in this process are noggin and chordin.
Follistatin and BMPs also participate in folliculogenesis within the ovary. The main role of follistatin is for progression of the follicle from early antral to antral/dominant in the oestrus/menstrus ovary. Follistatin is also involved in the promotion of cellular differentiation of estrogen—by converting granulosa cells (GC) to progesterone in the dominant follicle—and production of large lutein cells (LLC) in the corpus luteum.
Clinical significance
| Parts of this biology (those related to section) need to be updated. Please update this biology to reflect recent events or newly available information. (November 2019) |
Follistatin is studied for its role in regulation of muscle growth in mice, as an antagonist to myostatin (also known as GDF-8, a TGF superfamily member) which inhibits excessive muscle growth. Lee and McPherron demonstrated that inhibition of GDF-8, either by genetic elimination (knockout mice) or by increasing the amount of follistatin, resulted in increased muscle mass.[3][4] In 2009, research with macaque monkeys demonstrated that regulating follistatin via gene therapy also resulted in muscle growth and increases in strength.[5]
Increased levels of follistatin, by leading to increased muscle mass of certain core muscular groups, can increase life expectancy in cases of spinal muscular atrophy (SMA) in animal models.[6]
Elevated circulating follistatin levels are also associated with increased risk of type 2 diabetes, early death, heart failure, stroke and chronic kidney disease. It has been demonstrated that follistatin contributes to insulin resistance in type 2 diabetes development and nonalcoholic fatty liver disease (NAFLD). The genetic regulation of follistatin secretion from the liver is via Glucokinase regulatory protein (GCKR) identified by large GWAS studies.[7][8]. A recent publication highlights the activin-follistatin system as a regulator of kidney development and inflammation, thereby suggesting it as a therapeutic target.[9]
It is also investigated for its involvement in polycystic ovary syndrome (PCOS), in part to resolve debate as to its direct role in this disease.[10]
Sporadic inclusion body myositis, a variant of inflammatory myopathy, involves muscle weakness. In one clinical trial, rAAV1.CMV.huFS344, 6 × 1011 vg/kg, walk test results significantly improved versus untreated controls, along with decreased fibrosis and improved regeneration.
ACE-083, a follistatin-based fusion protein, was investigated for treatment focal or asymmetric myopathies. Intramuscular ACE-083 increased growth and force production in injected muscle in wild-type mice and mouse models of Charcot-Marie-Tooth disease (CMT) and Duchenne muscular dystrophy, without systemic effects or endocrine disruption.[11]
AAV-mediated FST reduced obesity-induced inflammatory adipokines and cytokines systemically and in synovial fluid. Mice receiving FST therapy were protected from post-traumatic osteoarthritis and bone remodeling from joint injury.[12]
In another mouse study, high dose animals showed significant quadriceps growth.
References
- ↑ "Isolation and partial characterization of follistatin: a single-chain Mr 35,000 monomeric protein that inhibits the release of follicle-stimulating hormone". Proceedings of the National Academy of Sciences of the United States of America 84 (23): 8282–8286. December 1987. doi:10.1073/pnas.84.23.8282. PMID 3120188. Bibcode: 1987PNAS...84.8282U.
- ↑ 2.0 2.1 "Human follistatin-related protein: a structural homologue of follistatin with nuclear localization". Endocrinology 142 (8): 3426–3434. August 2001. doi:10.1210/endo.142.8.8319. PMID 11459787.
- ↑ "Regulation of myostatin activity and muscle growth". Proceedings of the National Academy of Sciences of the United States of America 98 (16): 9306–9311. July 2001. doi:10.1073/pnas.151270098. PMID 11459935. Bibcode: 2001PNAS...98.9306L.
- ↑ "'Mighty mice' made mightier". http://www.eurekalert.org/pub_releases/2007-08/jhmi-mm082407.php.
- ↑ "Success Boosting Monkey Muscle Could Help Humans". NPR. 11 Nov 2009. https://www.npr.org/templates/story/story.php?storyId=120316010.
- ↑ "Delivery of recombinant follistatin lessens disease severity in a mouse model of spinal muscular atrophy". Human Molecular Genetics 18 (6): 997–1005. March 2009. doi:10.1093/hmg/ddn426. PMID 19074460.
- ↑ "Elevated circulating follistatin associates with an increased risk of type 2 diabetes". Nature Communications 12 (1): 6486. November 2021. doi:10.1038/s41467-021-26536-w. PMID 34759311. Bibcode: 2021NatCo..12.6486W.
- ↑ "Elevated circulating follistatin associates with increased risk of mortality and cardiometabolic disorders". Nutr Metab Cardiovasc Dis 34 (2): 418–425. 2024. doi:10.1016/j.numecd.2023.09.012. PMID 38000997.
- ↑ Nagayama. "The activin-follistatin system: Key regulator of kidney development, regeneration, inflammation, and fibrosis". Cytokine & Growth Factor Reviews. doi:10.1016/j.cytogfr.2024.11.004. https://www.sciencedirect.com/science/article/abs/pii/S1359610124000923?via%3Dihub. Retrieved 1 December 2025.
- ↑ "Identification of follistatin as a possible trait-causing gene in polycystic ovary syndrome". European Journal of Endocrinology 143 (4): 467–9. October 2000. doi:10.1530/eje.0.1430467. PMID 11022191.
- ↑ "Follistatin-based ligand trap ACE-083 induces localized hypertrophy of skeletal muscle with functional improvement in models of neuromuscular disease". Scientific Reports 9 (1): 11392. August 2019. doi:10.1038/s41598-019-47818-w. PMID 31388039. Bibcode: 2019NatSR...911392P.
- ↑ "Gene therapy for follistatin mitigates systemic metabolic inflammation and post-traumatic arthritis in high-fat diet-induced obesity". Science Advances 6 (19). May 2020. doi:10.1126/sciadv.aaz7492. PMID 32426485. Bibcode: 2020SciA....6.7492T.
Further reading
- "The structure of the follistatin:activin complex reveals antagonism of both type I and type II receptor binding". Developmental Cell 9 (4): 535–543. October 2005. doi:10.1016/j.devcel.2005.09.008. PMID 16198295.
- "Transgenic expression of a myostatin inhibitor derived from follistatin increases skeletal muscle mass and ameliorates dystrophic pathology in mdx mice". FASEB Journal 22 (2): 477–487. February 2008. doi:10.1096/fj.07-8673com. PMID 17893249.
- "Activin subunit and receptor expression in normal and cleft human fetal palate tissues". Pediatric and Developmental Pathology 10 (6): 436–445. 2007. doi:10.2350/06-05-0087.1. PMID 18001154.
- "Activin-type II receptor B (ACVR2B) and follistatin haplotype associations with muscle mass and strength in humans". Journal of Applied Physiology 102 (6): 2142–2148. June 2007. doi:10.1152/japplphysiol.01322.2006. PMID 17347381.
- "Follistatin suppresses the production of experimental multiple-organ metastasis by small cell lung cancer cells in natural killer cell-depleted SCID mice". Clinical Cancer Research 14 (3): 660–667. February 2008. doi:10.1158/1078-0432.CCR-07-1221. PMID 18245525.
- "Activin A and follistatin in menstrual blood: low concentrations in women with dysfunctional uterine bleeding". Reproductive Sciences 14 (4): 383–389. May 2007. doi:10.1177/1933719107303985. PMID 17644811.
- "High-density association study of 383 candidate genes for volumetric BMD at the femoral neck and lumbar spine among older men". Journal of Bone and Mineral Research 24 (12): 2039–2049. December 2009. doi:10.1359/jbmr.090524. PMID 19453261.
- "A Smad-binding element in intron 1 participates in activin-dependent regulation of the follistatin gene". The Journal of Biological Chemistry 283 (11): 7016–7026. March 2008. doi:10.1074/jbc.M709502200. PMID 18184649.
- "GLI2-specific transcriptional activation of the bone morphogenetic protein/activin antagonist follistatin in human epidermal cells". The Journal of Biological Chemistry 283 (18): 12426–12437. May 2008. doi:10.1074/jbc.M707117200. PMID 18319260.
- "Polymorphism of the follistatin gene in polycystic ovary syndrome". Molecular Human Reproduction 13 (4): 237–241. April 2007. doi:10.1093/molehr/gal120. PMID 17284512.
- "Deranged expression of follistatin and follistatin-like protein in women with ovarian endometriosis". Fertility and Sterility 88 (1): 200–205. July 2007. doi:10.1016/j.fertnstert.2006.11.105. PMID 17296189.
- "Biological activity of follistatin isoforms and follistatin-like-3 is dependent on differential cell surface binding and specificity for activin, myostatin, and bone morphogenetic proteins". Endocrinology 147 (7): 3586–3597. July 2006. doi:10.1210/en.2006-0089. PMID 16627583.
- "Deregulation of the activin/follistatin system in hepatocarcinogenesis". Journal of Hepatology 45 (5): 673–680. November 2006. doi:10.1016/j.jhep.2006.06.014. PMID 16935389.
- "Integrin alpha6beta4 controls the expression of genes associated with cell motility, invasion, and metastasis, including S100A4/metastasin". The Journal of Biological Chemistry 284 (3): 1484–1494. January 2009. doi:10.1074/jbc.M803997200. PMID 19011242.
- "FoxL2 and Smad3 coordinately regulate follistatin gene transcription". The Journal of Biological Chemistry 284 (12): 7631–7645. March 2009. doi:10.1074/jbc.M806676200. PMID 19106105.
- "Follistatin: a multifunctional regulatory protein". Frontiers in Neuroendocrinology 19 (4): 287–322. October 1998. doi:10.1006/frne.1998.0169. PMID 9799587.
- "Expression of inhibin-activin subunits, follistatin and smads in granulosa-luteal cells collected at oocyte retrieval". Journal of Assisted Reproduction and Genetics 23 (9–10): 385–392. 2006. doi:10.1007/s10815-006-9068-7. PMID 17053951.
- "Myostatin and follistatin polymorphisms interact with muscle phenotypes and ethnicity". Medicine and Science in Sports and Exercise 41 (5): 1063–1071. May 2009. doi:10.1249/MSS.0b013e3181930337. PMID 19346981.
- "Role of follistatin in promoting adipogenesis in women". The Journal of Clinical Endocrinology and Metabolism 94 (8): 3003–3009. August 2009. doi:10.1210/jc.2008-2005. PMID 19470636.
- "Activin and follistatin as local regulators in the human ovary". Biological Signals 5 (2): 81–89. 1996. doi:10.1159/000109177. PMID 8836491.
External links
- Follistatin at the US National Library of Medicine Medical Subject Headings (MeSH)
- Overview of all the structural information available in the PDB for UniProt: P19883 (Follistatin) at the PDBe-KB.
